Company registration number SC251033 (Scotland)
STONEHOUSE HOSPITALS LIMITED
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2023
STONEHOUSE HOSPITALS LIMITED
COMPANY INFORMATION
Directors
JS Gordon
PR Hepburn
(Appointed 8 February 2023)
PK Johnstone
(Appointed 20 December 2023)
Secretary
Resolis Limited
Company number
SC251033
Registered office
C/O Resolis Limited
Exchange Tower, 11th Floor
19 Canning Street
Edinburgh
United Kingdom
EH3 8EG
Auditor
Johnston Carmichael LLP
Bishop's Court
29 Albyn Place
Aberdeen
AB10 1YL
STONEHOUSE HOSPITALS LIMITED
CONTENTS
Page
Directors' report
1 - 2
Directors' responsibilities statement
3
Independent auditors' report
4 - 7
Statement of comprehensive income
8
Balance sheet
9
Statement of changes in equity
10
Notes to the financial statements
11 - 20
STONEHOUSE HOSPITALS LIMITED
DIRECTORS' REPORT
FOR THE YEAR ENDED 30 SEPTEMBER 2023
- 1 -

The directors present their annual report and financial statements for the year ended 30 September 2023.

Principal activities

The company continues to provide facilities management and building maintenance of the Stonehouse Hospitals NHS facility under a PFI/PPP contract entered in 2002. The facility remains a success and the company continues to operate in line with the financial model agreed at the re-financing date. The trading profit for the year is in line with the financial model and the company remains on target to meet its long-term financial targets. During the year, the company met all obligations and targets under the finance agreement.

The profit for the year after taxation and fair value movements on cash flow hedging instruments is £118,930 (2022: £583,186) as set out in the Statement of Comprehensive Income on page 8. The profit for the year will be transferred to reserves.

Results and dividends

During the year, the Company did not pay out any dividends (2022: £8,000). The directors do not recommend the payment of a dividend as at 30th September 2023 (2022: £nil).

Directors

The directors who held office during the year and up to the date of signature of the financial statements were as follows:

JS Gordon
R W Christie
(Resigned 8 February 2023)
PR Hepburn
(Appointed 8 February 2023)
J McDonagh
(Appointed 1 March 2023 and resigned 20 December 2023)
PK Johnstone
(Appointed 20 December 2023)
Financial instruments

Due to the nature of the company’s business, the financial risks the directors consider relevant to the company are credit, interest rate, cash flow and liquidity risk.

Credit Risk

The credit risk of the FM provider represents the major credit risk to the company. Periodic checks of the financial strength of the FM provider are undertaken.

Interest Rate Risk

The financial risk management objectives of the company are to ensure that the financial risks are mitigated by the use of financial instruments. The company uses interest rate swaps to reduce its exposure to interest rate movements. Financial instruments are not used for speculative purposes.

STONEHOUSE HOSPITALS LIMITED
DIRECTORS' REPORT (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2023
- 2 -
Cash flow and liquidity Risk

The company’s cash flow and liquidity risk is principally managed through financing the company by means of long term borrowing.

Going concern

The directors have prepared a detailed model forecast to project completion incorporating the relevant terms of the PFI contract, subcontracts and Credit Agreement and reasonably prudent economic assumptions. This forecast and associated business model, which is updated regularly, predicts that the Company will be profitable and will have sufficient cash resources to operate within the terms of the PFI contract, Subcontract and Credit Agreement. Therefore, the directors, having considered the financial position of the Company and its expected future cash flows, have prepared the financial statements on a going concern basis. The directors confirm that they do not intend to liquidate the Company or cease trading as we consider we have realistic alternatives to doing so.

 

The directors confirm the completeness of the information provided regarding events and conditions relating to going concern at the date of approval of the financial statements, including plans for future actions.

 

Auditor

In accordance with the company’s articles, a resolution proposing that Johnston Carmichael LLP be reappointed as auditor of the company will be put at a general meeting.

Statement of disclosure to auditor

So far as each person who was a director at the date of approving this report is aware, there is no relevant audit information of which the company’s auditor is unaware. Additionally, the directors individually have taken all the necessary steps that they ought to have taken as directors in order to make themselves aware of all relevant audit information and to establish that the company’s auditor is aware of that information.

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies’ exemption.

 

On behalf of the board
PR Hepburn
Director
29 February 2024
STONEHOUSE HOSPITALS LIMITED
DIRECTORS' RESPONSIBILITIES STATEMENT
FOR THE YEAR ENDED 30 SEPTEMBER 2023
- 3 -

The directors are responsible for preparing the Directors’ Report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company’s transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

STONEHOUSE HOSPITALS LIMITED
INDEPENDENT AUDITORS' REPORT
TO THE MEMBER OF STONEHOUSE HOSPITALS LIMITED
- 4 -
Opinion

We have audited the financial statements of Stonehouse Hospitals Limited (the 'company') for the year ended 30 September 2023 which comprise the statement of comprehensive income, balance sheet, statement of changes in equity and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice). In our opinion the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

 

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

 

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditors' report thereon. The directors are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

 

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

 

STONEHOUSE HOSPITALS LIMITED
INDEPENDENT AUDITORS' REPORT (CONTINUED)
TO THE MEMBER OF STONEHOUSE HOSPITALS LIMITED
- 5 -
Matters on which we are required to report by exception

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the directors' report.

 

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

 

Responsibilities of directors

As explained more fully in the directors' responsibilities statement set out on page 3, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditors' responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

 

A further description of our responsibilities is available on the Financial Reporting Council’s website at: https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Extent the audit was considered capable of detecting irregularities, including fraud

 

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.

We assessed whether the engagement team collectively had the appropriate competence and capabilities to identify or recognise non-compliance with laws and regulations by considering their experience, past performance and support available.

All engagement team members were briefed on relevant identified laws and regulations and potential fraud risks at the planning stage of the audit. Engagement team members were reminded to remain alert to any indications of fraud or non-compliance with laws and regulations throughout the audit.

STONEHOUSE HOSPITALS LIMITED
INDEPENDENT AUDITORS' REPORT (CONTINUED)
TO THE MEMBER OF STONEHOUSE HOSPITALS LIMITED
- 6 -

We obtained an understanding of the legal and regulatory frameworks that are applicable to the company and the sector in which it operates, focusing on those provisions that had a direct effect on the determination of material amounts and disclosures in the financial statements. The most relevant frameworks we identified include:

 

We gained an understanding of how the company is complying with these laws and regulations by making enquiries of management and those charged with governance. We corroborated these enquiries through our review of relevant correspondence with regulatory bodies and board meeting minutes.

We assessed the susceptibility of the financial statements to material misstatement, including how fraud might occur, by meeting with management and those charged with governance to understand where it was considered there was susceptibility to fraud. This evaluation also considered how management and those charged with governance were remunerated and whether this provided an incentive for fraudulent activity. We considered the overall control environment and how management and those charged with governance oversee the implementation and operation of controls. We identified a heightened fraud risk in relation to:

In addition to the above, the following procedures were performed to provide reasonable assurance that the financial statements were free of material fraud or error:

Our audit procedures were designed to respond to the risk of material misstatements in the financial statements, recognising that the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve intentional concealment, forgery, collusion, omission or misrepresentation. There are inherent limitations in the audit procedures performed and the further removed non-compliance with laws and regulations is from the events and transactions reflected in the financial statements, the less likely we would become aware of it.

STONEHOUSE HOSPITALS LIMITED
INDEPENDENT AUDITORS' REPORT (CONTINUED)
TO THE MEMBER OF STONEHOUSE HOSPITALS LIMITED
- 7 -

Use of our report

This report is made solely to the company's member in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's member those matters we are required to state to the member in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's member for our audit work, for this report, or for the opinions we have formed.

Jenny Junnier
Senior Statutory Auditor
For and on behalf of Johnston Carmichael LLP
29 February 2024
Chartered Accountants
Statutory Auditor
Bishop's Court
29 Albyn Place
Aberdeen
AB10 1YL
STONEHOUSE HOSPITALS LIMITED
STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 30 SEPTEMBER 2023
- 8 -
Year
Period
ended
ended
30 September
30 September
2023
2022
Notes
£'000
£'000
Turnover
3
1,238
575
Cost of sales
(861)
(185)
Gross profit
377
390
Administrative expenses
(142)
(144)
Operating profit
235
246
Interest receivable and similar income
3
113
119
Interest payable and similar expenses
5
(180)
(197)
Profit before taxation
168
168
Tax on profit
(37)
(32)
Profit for the financial year
131
136
Other comprehensive income
Cash flow hedges (loss)/gain arising in the year
(16)
596
Tax relating to other comprehensive income
4
(149)
Total comprehensive income for the year
119
583

The profit and loss account has been prepared on the basis that all operations are continuing operations.

 

The notes on pages 11 to 20 form part of the financial statements.

STONEHOUSE HOSPITALS LIMITED
BALANCE SHEET
AS AT
30 SEPTEMBER 2023
30 September 2023
- 9 -
2023
2022
Notes
£'000
£'000
£'000
£'000
Current assets
Debtors falling due after more than one year
7
2,094
2,242
Debtors - deferred tax
14
4
-
0
Debtors falling due within one year
7
706
417
Cash at bank and in hand
623
492
3,427
3,151
Creditors: amounts falling due within one year
9
(568)
(300)
Net current assets
2,859
2,851
Creditors: amounts falling due after more than one year
10
(2,184)
(2,295)
Net assets
675
556
Capital and reserves
Called up share capital
15
33
33
Hedging reserve
(11)
1
Profit and loss reserves
653
522
Total equity
675
556

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

 

The notes on pages 11 to 20 form part of the financial statements.

The financial statements were approved by the board of directors and authorised for issue on 29 February 2024 and are signed on its behalf by:
PR Hepburn
Director
Company Registration No. SC251033
STONEHOUSE HOSPITALS LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 30 SEPTEMBER 2023
- 10 -
Share capital
Hedging reserve
Profit and loss reserves
Total
Notes
£'000
£'000
£'000
£'000
Balance at 1 September 2021
33
(446)
394
(19)
Period ended 30 September 2022:
Profit for the period
-
-
136
136
Other comprehensive income:
Cash flow hedges gains
-
596
-
596
Tax relating to other comprehensive income
-
(149)
-
0
(149)
Total comprehensive income for the period
-
447
136
583
Dividends
6
-
-
(8)
(8)
Balance at 30 September 2022
33
1
522
556
Period ended 30 September 2023:
Profit for the period
-
-
131
131
Other comprehensive income:
Cash flow hedges gains
-
(16)
-
(16)
Tax relating to other comprehensive income
-
4
-
0
4
Total comprehensive income for the period
-
(12)
131
119
Balance at 30 September 2023
33
(11)
653
675
STONEHOUSE HOSPITALS LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2023
- 11 -
1
Accounting policies
Company information

Stonehouse Hospitals Limited is a private company limited by shares incorporated in Scotland. The registered office is C/O Resolis Limited, Exchange Tower, 11th Floor, 19 Canning Street, Edinburgh, United Kingdom, EH3 8EG.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £'000.

The financial statements have been prepared under the historical cost convention, modified to include certain financial instruments at fair value. The principal accounting policies adopted are set out below.

 

Basis of preparation

The preparation of financial statements in conformity with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the company’s accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements, are disclosed further in the accounting policies.

 

The principal accounting policies adopted are set out below have been consistently applied to the years presented, unless otherwise stated.

1.2
Going concern

The directors have prepared a detailed model forecast to project completion incorporating the relevant terms of the PFI contract, subcontracts and Credit Agreement and reasonably prudent economic assumptions. This forecast and associated business model, which is updated regularly, predicts that the Company will be profitable and will have sufficient cash resources to operate within the terms of the PFI contract, Subcontract and Credit Agreement. Therefore, the directors, having considered the financial position of the Company and its expected future cash flows, have prepared the financial statements on a going concern basis. The directors confirm that they do not intend to liquidate the Company or cease trading as we consider we have realistic alternatives to doing so.true

 

The directors confirm the completeness of the information provided regarding events and conditions relating to going concern at the date of approval of the financial statements, including plans for future actions.

1.3
Reporting period

Last reporting period the company changed its accounting period end from 31 August 2022 to 30 September 2022 to bring the financial statements in line with lender reporting deadlines. Previously the company had prepared financial statements for the financial year from 1 September 2020 to 31 August 2021. The reporting period reverted back to a 12-month period from 1 October 2022. The comparative period being from 1 September 2021 to 30 September 2022 is therefore not entirely comparable.

1.4

Finance Debtor

The Company has taken advantage of the transition exemption in FRS 102 Section 35.10(i) that allows the Company to continue the service concession arrangement accounting policies from previous UK GAAP.

 

The company is accounting for the concession asset based on the ability to substantially transfer all the risks and rewards of ownership to the customer, with this arrangement the costs incurred by the company on the design and construction of the assets have been treated as a finance debtor within these financial statements.

STONEHOUSE HOSPITALS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2023
1
Accounting policies
(Continued)
- 12 -
1.5
Revenue recognition

Turnover represents the services' share of the management services income received by the company for the provision of a PFI asset to the customer. This income is received over the life of the concession period. Management service income is allocated between turnover, finance debtor interest and reimbursement of finance debtor so as to generate a constant rate of return in respect of the finance debtor over the life of the contract. Turnover is represented net of VAT.

1.6
Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term highly liquid investments with original maturities of six months or less and bank overdrafts.

 

The lifecycle and debt service reserve accounts must be maintained at a level which is higher than the lifecycle reserve and debt service reserve amounts. These amounts vary during the year so cash levels are monitored to ensure that appropriate levels are maintained. Cash is therefore not freely available from these accounts.

 

Restricted cash

Cash at bank includes £492,168 (2022: £392,000) held in reserve accounts. Restrictions are placed on the use of these funds being held in the company's reserve accounts under the terms of its Senior Loan facility.

1.7
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102, in full, to all of its financial instruments. A financial asset or a financial liability is recognised only when the entity becomes a party to the contractual provisions of the instrument.

 

Basic financial instruments are initially recognised at the transaction price and subsequently at amortised cost, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

 

Debt instruments are initially recognised at the present value of cash payable to the lender and are subsequently measured at amortised cost using the effective interest rate method, less impairment. The effective interest rate method is the rate that exactly discounts estimated future cash payments or receipts through the expected life of the financial instrument. The effective interest rate amortisation is included in interest payable and similar charges in the Statement of Comprehensive Income.

 

Other financial instruments are subsequently measured at fair value, with any changes recognised in the Statement of Comprehensive Income, with the exception of hedging instruments in a designated hedging relationship.

 

Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in the Statement of Comprehensive Income immediately.

 

For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets are either assessed individually or grouped on the basis of similar credit risk characteristics.

 

Any reversals of impairment are recognised in the Statement of Comprehensive Income immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised. Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the entity after deducting all of its financial liabilities.

STONEHOUSE HOSPITALS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2023
1
Accounting policies
(Continued)
- 13 -

Where the contractual obligations of financial instruments (including share capital) are equivalent to a similar debt instrument, those financial instruments are classed as financial liabilities. Financial liabilities are presented as such in the Statement of Financial Position. Finance costs and gains or losses relating to financial liabilities are included in the Statement of Comprehensive Income. Finance costs are calculated so as to produce a constant rate of return on the outstanding liability.

 

Where the contractual terms of share capital do not have any terms meeting the definition of a financial liability then this is classed as an equity instrument. Dividends and distributions relating to equity instruments are debited direct to equity.

1.8
Hedge accounting

The company has entered into an arrangement with third parties that is designed to hedge future cash flows arising on variable rate interest loan arrangements, with the net effect of exchanging the cash flows arising under those arrangements for a stream of fixed interest cash flows ("interest rate swaps").

 

To qualify for hedge accounting, documentation is prepared specifying the hedging strategy, the component transactions and methodology used for effectiveness measurement. Changes in the carrying value of financial instruments that are designated and effective as hedges of future cash flows ("cash flow hedges") are recognised directly in a hedging reserve in equity and any ineffective portion is recognised immediately in the Statement of Comprehensive Income. Amounts deferred in equity in respect of cash flow hedges are subsequently recognised in the Statement of Comprehensive Income in the same period in which the hedged item affects net profit or loss or the hedging relationship is terminated, and the underlying position being hedged has been extinguished.

1.9
Taxation

Taxation expense for the period comprises current and deferred tax recognised in the reporting period. Tax is recognised in the Statement of Comprehensive Income, except to the extent that it relates to items recognised in Other Comprehensive Income or directly in equity. In this case tax is also recognised in Other Comprehensive Income or directly in equity respectively.

 

Current or deferred taxation assets and liabilities are not discounted.

Current tax

Current tax is the amount of income tax payable in respect of the taxable profit for the year or prior years. Tax is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the period end.

 

The directors periodically evaluate positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation and establish provisions where appropriate on the basis of amounts expected to be paid to the tax authorities.

Deferred tax

Deferred tax arises from timing differences that are differences between taxable profits and total comprehensive income as stated in the financial statements. These timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements.

 

Deferred tax is recognised on all timing differences at the reporting date except for certain exceptions. Unrelieved tax losses and other deferred tax assets are only recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is also recognised on the revaluations of derivative financial instruments, with the movements going through the Statement of Comprehensive Income.

 

Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the period end and that are expected to apply to the reversal of the deferred tax asset or liability.

STONEHOUSE HOSPITALS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2023
1
Accounting policies
(Continued)
- 14 -
1.10

Disclosure exemptions

The company has taken advantage of the exemption in FRS 102 Section 7 ‘Statement of Cash Flows’ part 1B, which states that a small company is not required to prepare a cash flow statement.

 

The company has taken advantage of the exemption in Section 33 of FRS 102 ‘Related Party Disclosures’, that allows it not to disclose transactions with wholly owned members of a group.

2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Critical judgements

The judgement (apart from those involving estimations) that management has made in the process of applying the entity's accounting policies and that has the most significant effect on the amounts recognised in the financial statements is as follows:

 

Hedge accounting and consideration of the fair value of derivative financial instruments

The company uses a derivative financial instrument to hedge certain economic exposures in relation to movements in interest rates as compared with the position that was expected at the date the underlying transaction being hedged was entered into. The company fair values its derivative financial instrument and records the fair value of the swap instrument on its Statement of Financial Position. No market prices are available for this instrument and consequently the fair value is derived using financial models developed by the lender based on counterparty information that is independent of the company but uses observable market data in respect of interest rates as an input to valuing the derivative financial instrument. There is also a judgement on whether an economic hedge relationship exists in order to achieve hedge accounting. Appropriate documentation has been prepared detailing the economic relationship between the hedging instrument and the underlying loan being hedged.

 

The effective interest rate on senior debt instruments was calculated and is not deemed to be materially different to the interest rate applied in the financial statement and as such no adjustment has been made to the interest charge in the financial statements. This will continue to be monitored.

Key sources of estimation uncertainty

Accounting estimates and assumptions are made concerning the future and, by their nature, will rarely equal the related actual outcome. The key assumptions and other sources of estimation uncertainty are as follows:

 

Accounting for service concession arrangements

Accounting for the service concession contract and finance debtors requires estimation of service margins, finance debtor interest rates and associated amortisation profile which is based on forecast results of the contract. These were forecast initially within the operating model at financial close monitored throughout the duration of the project.

STONEHOUSE HOSPITALS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2023
- 15 -
3
Turnover and other revenue

The turnover and profit before tax arose entirely within the United Kingdom and through one principal activity.

2023
2022
£'000
£'000
Turnover analysed by class of business
Service Fee
1,238
575
2023
2022
£'000
£'000
Other revenue
Interest income
113
119
4
Directors' remuneration

The directors, who are also key management personnel, received no emoluments from the company during the year for their services as directors. There are no other employees of the Company.

 

George Street Capital Limited, the parent company of Stonehouse Hospitals Limited, received the fees of £19,059 (2022: £18,485) from the Company in respect of the services of J S Gordon, P R Hepburn, J McDonagh, and R Christie as directors.

5
Interest payable and similar expenses
2023
2022
£'000
£'000
Interest on financial liabilities measured at amortised cost:
Interest on bank and subordinated debt
180
197
6
Dividends
2023
2022
£'000
£'000
Dividend paid on ordinary shares
-
0
8
7
Debtors
2023
2022
Amounts falling due within one year:
£'000
£'000
Finance Debtor - due within 1 year
147
137
Other debtors
304
204
Prepayments and accrued income
255
76
706
417
STONEHOUSE HOSPITALS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2023
7
Debtors
(Continued)
- 16 -
2023
2022
Amounts falling due after more than one year:
£'000
£'000
Derivative financial instruments
-
0
1
Finance Debtor - due after more than 1 year
2,094
2,241
2,094
2,242
Deferred tax asset (note 14)
4
-
0
2,098
2,242
Total debtors
2,804
2,659

The finance debtor represents payments due from NHS Trust in respect of the Project Agreement. These payments are receivable over the remaining life of the agreement.

 

The movement in the finance debtor is analysed as follows:

2023
2022
£'000
£'000
At beginning of year
2,378
2,517
Repayments received
(137)
(139)
At end of year
2,241
2,378
8
Financial instruments
2023
2022
£'000
£'000
Carrying amount of financial assets
Instruments measured at fair value through profit or loss
-
1
Carrying amount of financial liabilities
Measured at fair value through profit or loss
- Derivative financial instruments
15
-
STONEHOUSE HOSPITALS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2023
8
Financial instruments
(Continued)
- 17 -

Hedge accounting

 

Derivatives are financial instruments that derive their value from the price of an underlying item, such as interest rates or other indices. The Company's use of derivative financial instruments is described below.

 

Interest rate swaps

 

The Company has entered into an interest rate swap with a third party for the same notional amount as the Company's variable rate borrowings with banks which has the commercial effect of swapping the variable rate interest coupon on those loans for a fixed rate coupon. The bank loans and related interest rate swaps amortise at the same rate over the life of the loan/swap arrangements. The interest rate swap was entered into at a fixed interest rate of 5.91% in June 2006 and expires in September 2032.

 

The directors believe that the hedging relationship between the interest rate swap and related variable rate bank loan is highly effective and, as a consequence have concluded that these derivatives meet the definition of a cash flow hedge and have formally designated them as such.

 

The Company's derivative financial instrument is carried at fair value, based on broker quotes. Those quotes are tested for reasonableness by discounting estimated future cash flows based on the terms and maturity of each contract and using market interest rates for a similar instrument at the measurement date.

 

The carrying value of the interest swap at 30 September 2023 amounted to an liability of £15,105 (2022: an asset of £679). The movements during the year in the fair value of the interest rate swap is a debit of £11,838 (2022: £446,912 credit) which has been recorded in the cashflow hedge reserve and £3,946 debit (2022: £148,970 credit) to deferred tax.

9
Creditors: amounts falling due within one year
2023
2022
Notes
£'000
£'000
Bank loans
11
125
120
Trade creditors
10
-
0
Corporation tax
3
44
Other taxation and social security
12
31
Accruals and deferred income
418
105
568
300

Included within accruals and deferred income are amounts recognised in respect of future payments due to lifecycle underspend of £162,350 (2022: £55,202), the timing of which is uncertain.

10
Creditors: amounts falling due after more than one year
2023
2022
Notes
£'000
£'000
Bank loans and overdrafts
11
1,705
1,831
Loans from group undertakings
11
464
464
Derivative financial instruments
15
-
0
2,184
2,295
STONEHOUSE HOSPITALS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2023
10
Creditors: amounts falling due after more than one year
(Continued)
- 18 -

The senior debt is repayable in bi-annual instalments which commenced in June 2006. The final repayment date is September 2032.

 

The senior debt bears interest based on SONIA. As part of its interest rate management strategy the company entered into an interest rate swap agreement in respect of the debt maturing in September 2032. Under this swap the company pays interest at a fixed rate of 4.96%.

 

The loan is secured by a floating charge and standard security over the assets of the company.

 

Other loans relate to subordinate debt which carries an interest rate of 14%. The principal is repayable on 30 September 2032.

11
Loans and overdrafts
An analysis of the maturity of loans is given below:
2023
2022
£'000
£'000
Amounts falling due within one year or on demand:
Senior secured loan
125
120
125
120
Amounts falling due between one and two years:
Senior secured loan
190
125
190
125
Amounts falling due between two and five years:
Senior secured loan
655
619
655
619
Amounts falling due after more than five years:
Repayable by instalments
Senior secured loan
860
1,087
Loans from group undertakings
464
464
1,324
1,551
The total cash repayable on the loan is as follows :
Bank loans
1,830
1,951
Loans from group undertakings
464
464
2,294
2,415
Payable within one year
125
120
Payable after one year
2,169
2,295
STONEHOUSE HOSPITALS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2023
- 19 -
12
Related Party Transactions

The company has taken advantage of the exemption available in FRS 102 section 33 from the requirement to disclose related party transactions with wholly owned group companies.

Cobalt Project Investments Ltd
2023
2022
£'000
£'000
Group Relief
11
-
13
Immediate and ultimate holding Company

George Street Capital Limited is the immediate parent entity. The ultimate controlling entity is considered to be Dalmore Capital Fund LP, a limited partnership registered in England and Wales. The registered office of Dalmore Capital Fund LP is 1 Park Row, Leeds, LS1 5AB. Copies of the financial statements of Dalmore Capital Fund LP are available from the General Partner at C/O Dalmore Capital Limited, Caledonian Exchange, 19a Canning Street, Edinburgh, EH3 8EG.

14
Deferred taxation

Deferred tax has been provided for at 25% (2022: 25%) in the financial statements and is set out below:

Assets
Assets
2023
2022
Balances:
£'000
£'000
Deferred tax asset
4
-
2023
Movements in the year:
£'000
Liability at 1 October 2022
-
Credit to other comprehensive income
(4)
Asset at 30 September 2023
(4)

The deferred tax asset will unwind over the life of the hedge which expires in September 2032.

 

No portion of the deferred tax balance is likely to be recovered or settled in the 12 months following the Statement of Financial Position date.

15
Share capital
2023
2022
2023
2022
Ordinary share capital
Number
Number
£'000
£'000
Issued and fully paid
of £1 each
33,000
33,000
33
33
STONEHOUSE HOSPITALS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2023
- 20 -
16
Reserves

The company has two main reserves:

 

Hedging reserve - This reserve records fair value movements on cash flow hedging instruments.

Retained earnings - This reserve records retained earnings and accumulated losses.

2023-09-302022-10-01falseCCH SoftwareCCH Accounts Production 2023.300JS GordonR W ChristiePR HepburnJ McDonaghPK JohnstoneResolis Limitedfalse0SC2510332022-10-012023-09-30SC251033bus:Director12022-10-012023-09-30SC251033bus:Director32022-10-012023-09-30SC251033bus:Director52022-10-012023-09-30SC251033bus:CompanySecretary12022-10-012023-09-30SC251033bus:Director22022-10-012023-09-30SC251033bus:Director42022-10-012023-09-30SC251033bus:RegisteredOffice2022-10-012023-09-30SC2510332023-09-30SC2510332021-09-012022-09-30SC251033core:RetainedEarningsAccumulatedLosses2021-09-012022-09-30SC251033core:RetainedEarningsAccumulatedLosses2022-10-012023-09-30SC251033core:HedgingReserve2022-10-012023-09-30SC251033core:HedgingReserve2021-09-012022-09-30SC251033core:Non-currentFinancialInstrumentscore:AfterOneYear2023-09-30SC251033core:Non-currentFinancialInstrumentscore:AfterOneYear2022-09-30SC251033core:CurrentFinancialInstruments2023-09-30SC251033core:CurrentFinancialInstruments2022-09-30SC251033core:Non-currentFinancialInstruments2023-09-30SC251033core:Non-currentFinancialInstruments2022-09-30SC2510332022-09-30SC251033core:CurrentFinancialInstrumentscore:WithinOneYear2023-09-30SC251033core:CurrentFinancialInstrumentscore:WithinOneYear2022-09-30SC251033core:ShareCapital2023-09-30SC251033core:ShareCapital2022-09-30SC251033core:HedgingReserve2023-09-30SC251033core:HedgingReserve2022-09-30SC251033core:RetainedEarningsAccumulatedLosses2023-09-30SC251033core:RetainedEarningsAccumulatedLosses2022-09-30SC251033core:ShareCapital2021-08-31SC251033core:HedgingReserve2021-08-31SC251033core:RetainedEarningsAccumulatedLosses2021-08-31SC2510332021-08-31SC251033core:CurrentFinancialInstrumentscore:FinancialInstrumentsAmortisedCost2023-09-30SC251033bus:PrivateLimitedCompanyLtd2022-10-012023-09-30SC251033bus:FRS1022022-10-012023-09-30SC251033bus:Audited2022-10-012023-09-30SC251033bus:FullAccounts2022-10-012023-09-30xbrli:purexbrli:sharesiso4217:GBP